Zobacz wszystkie

Biofrontera AG: Biofrontera AG: First Ameluz? sales in Central Eastern European region

2014-08-06 08:00:00
Ticker Giełda ISIC Kraj Miasto
B8F XFRA Germany Leverkusen


Biofrontera AG /

Biofrontera AG: First Ameluz? sales in Central Eastern European region

. Processed and transmitted by NASDAQ OMX Corporate Solutions.

The issuer is solely responsible for the content of this announcement.



Leverkusen, 6 August 2014 - Biofrontera (AIM/FSE:B8F), the European

biopharmaceutical company, has started selling its prescription drug Ameluz(?)

for the treatment of actinic keratosis in Slovenia, representing the first

Ameluz(?) sales in a Central Eastern European country. Biofrontera Pharma GmbH

is the official distributor in Slovenia, working in conjunction with its local

partner PHA FARMED d.o.o., Ljubljana. The PDT treatment and Ameluz(?) are fully

reimbursed by the public health care system in Slovenia.



Four clinics have now introduced PDT with Biofrontera's PDT lamp BF-RhodoLED(?)

and had first Ameluz(?) prescriptions, already an excellent coverage for a small

country such as Slovenia. Ameluz(?) PDT is now available at the



* Derma Centre Maribor.

* University Clinical Centre in Ljubljana University Dermatovenerological

Clinic.

* University Medical Centre in Maribor, Department of Dermatology and

Venereal Diseases.

* General Hospital in Celje, Department of Dermatovenerology.



Dermatologist Dr. Sandi Luft, founder of the Derma Centre Maribor, is the first

who started using PDT with BF-RhodoLED(?) and Ameluz(?) in Slovenia:

"At first, I always prioritize patient and the treatment results. If the

efficiency of the treatment is satisfying, I am very confident to recommend the

therapy to my professional colleges and other patients. Actinic keratosis is a

common skin disease, which is recently successfully treated by PDT. Derma Centre

Maribor has just implemented PDT with BF-RhodoLED(? )and the medicine Ameluz(?).

The results show that no more than two visits of patients are needed to achieve

almost complete clearance, which is not common with other available treatments

of actinic keratosis. I can only confirm that my patients are very satisfied

also with the excellent cosmetic result."



Slavica Camer, CEO of the local representative PHA FARMED, commented: "All the

healthcare stakeholders in Slovenia have agreed on the value of PDT with

Ameluz(?). The national regulators and insurance companies have recognised the

fact that this treatment option is, due to its unmatched clearance rates, saving

money for the health care system in the long run, and have made full

reimbursement possible. Consequently, patients in Slovenia have now the

possibility to be treated with the most efficient treatment option available for

the indication."





Enquiries



Biofrontera AG +49 (0) 214 87 63 2 0

Prof. Hermann Lübbert, Chief Executive Officer press@biofrontera.com

Thomas Schaffer , Chief Financial Officer www.biofrontera.com

Anke zur Mühlen, Corporate Communications



Brainwell Asset Solutions +49 (0) 152 08931514

Jürgen Benker



finnCap (Nomad and Broker) +44(0) 20 7220 0500

Geoff Nash / Christopher Raggett (Corporate Finance)

Steven Norcross(Corporate Broking)



Seton Services Limited (IR) +44 (0) 20 7603 6797

Toni Vallen



Gable Communications +44 (0) 20 7193 7463

Justine James / John Bick +44 (0) 7872 061007









Notes to Editors:



Biofrontera AG (AIM/FSE: B8F, ISIN DE0006046113) is a biopharmaceutical company

specialising in the development and distribution of dermatological drugs and

medical cosmetics for the treatment and care of skin diseases. Biofrontera's

main product is Ameluz(?), a prescription drug approved for use in Europe for

the treatment of mild to moderate Actinic Keratosis (superficial skin cancer) by

photodynamic therapy (light therapy). Biofrontera is the first small German

pharmaceutical company to receive a centralized approval for a drug developed

in-house. The Company is looking to further develop Ameluz(?) for use in Basal

Cell Carcinoma and is currently progressing through regulatory approvals to sell

the product in other territories, in particular the largest pharmaceutical

market, the USA.



In addition, the Company markets the Belixos(?) cosmetic series with plant

extracts, currently available in cream and liquid formulations which offer

nurturing and regenerating effects for people suffering from pruritus, dry skin

or chronic ailments such as eczema or psoriasis.



Biofrontera group was founded in 1997 by Prof. Dr. Hermann Lübbert, the CEO, and

is headquartered in Leverkusen, Germany.



www.biofrontera.com





This press release contains forward-looking statements based on the currently

held beliefs and assumptions of the management of Biofrontera AG, which are

expressed in good faith and, in their opinion, reasonable. Forward-looking

statements involve known and unknown risks, uncertainties and other factors,

which may cause the assumptions expressed or implied in this press release to be

faulty. Given these risks, uncertainties and other factors, recipients of this

document are cautioned not to place undue reliance on the forward-looking

statements. Biofrontera AG disclaims any obligation to update these forward-

looking statements to reflect future events or developments.









This announcement is distributed by GlobeNewswire on behalf of

GlobeNewswire clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and

other applicable laws; and

(ii) they are solely responsible for the content, accuracy and

originality of the information contained therein.



Source: Biofrontera AG via GlobeNewswire

[HUG#1846669]





podstrony